Please login to the form below

Not currently logged in
Email:
Password:

CureVac

This page shows the latest CureVac news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolts on another immuno-oncology company

Boehringer bolts on another immuno-oncology company

Immunotherapeutics and earlier alliances with Siamab, AbeXXa Biologics, CureVac and Philogen.

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    805. Curevac / Boehringer Ingelheim. Licence and collaboration. Messenger RNA vaccine (CV9202) in combination with afatininib and chemo-radiation for lung cancer.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Boehringer Ingelheim has taken a licence to Curevac's messenger RNA vaccine for one of its compounds and the Californian company, Sutro, has signed an early stage deal with Merck KGaA

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    preclinical). 225. CureVac/ Sanofi Pasteur. Exercise of option,  licence. RNActive vaccine technology vs undisclosed pathogens (preclinical).

  • Pharma deals during July 2014 Pharma deals during July 2014

    Scandinavia. CureVac's relationship with Sanofi Pasteur dates back to 2011 when the companies entered into a collaboration and option agreement covering mRNA-based vaccines generated using CureVac's RNActive technology ... It will pay CureVac an

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • CureVac’s CEO appointed to EC High Level Group CureVac’s CEO appointed to EC High Level Group

    Dr Ingmar Hoerr, chief executive officer of clinical-stage mRNA technology specialist CureVac, has been appointed to the European Commission's High Level Group for research and innovation programmes. ... He brings 17 years of experience as the founder

  • CureVac appoints chief financial officer CureVac appoints chief financial officer

    Pierre Kemula joins the mRNA company’s management board. Tübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer. ... Kemula will have responsibility for managing CureVac's financial and capital markets

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics